

Children with Newly Diagnosed Type 1 Diabetes Before and During the COVID-19 Pandemic

✉ Rujittika Mungmunpantipantip¹, ✉ Viroj Wiwanitkit²

¹Private Academic Consultant, Bangkok, Thailand

²Dr DY Patil University, Pune, India

Keywords: Children, diabetes, COVID-19

Dear Editor,

We would like to share ideas on the publication “A Long-Term Comparison of Presenting Characteristics of Children with Newly Diagnosed Type 1 Diabetes Before and During the COVID-19 Pandemic” (1). Kaya et al. (1) noted that increased frequency and severity of diabetic ketoacidosis (DKA) was observed in children with newly diagnosed with type 1 diabetes (T1DM) during the pandemic, and the results justify concerns about the diagnosis of other diseases during the pandemic. Kaya et al. (1) also stated that diabetes symptom recognition studies should be continued regularly to reach all parts of society during a pandemic. We agree that Coronavirus disease-2019 (COVID-19) can cause endocrine disruption and its correlation with diabetes is interesting. Severe acute respiratory syndrome-Coronavirus-2 may promote the beginning of T1DM and may hasten the emergence of DKA in juvenile diabetic patients, according to a report by Albuali and AlGhamdi (2), even in the absence of respiratory symptoms.

Kaya et al. (1) has found an increased frequency and severity of DKA in children with newly diagnosed T1DM in the pandemic period, and they are concerned about the diagnosis of other diseases during the pandemic. Although there might be limitation on controlling of confounding factors due to nature of a retrospective study based on records review, Kaya et al. (1) point to some interesting findings. Possible pathological associations may be due to an abnormal immune response/inflammation or increased blood viscosity due to COVID-19 (3,4,5). In brief, the pathogen might induce abnormal immunity

that can directly attack islet cell or there might be hyperinflammatory process that can result in DKA (3,4). Additionally, the increased blood viscosity is a common observation in COVID-19 case (6). The hyperviscosity induced by COVID-19 might also be a triggering factor for DKA development (5). The current study has been able to show that there are no significant effects of immune/autoantibodies. The observation on no significant effects of immune/autoantibodies can be further interpreted in term of possible exact pathophysiology of DKA. Based on the data from the present study, the pathogenesis of DKA should be unlikely to be associated with abnormal immune response. This may mean that changes in blood viscosity after COVID-19 may contribute to the development of DKA.

Ethics

Peer-review: Internally peer-reviewed.

Authorship Contributions

Concept - Design - Data Collection or Processing - Analysis or Interpretation - Writing: Rujittika Mungmunpantipantip, Viroj Wiwanitkit.

Financial Disclosure: The authors declared that this study received no financial support.

References

1. Kaya G, Cimbeke EA, Yeşilbaş O, Bostan YE, Karagüzel G. A Long-Term Comparison of Presenting Characteristics of Children with Newly Diagnosed Type 1 Diabetes Before and During the COVID-19 Pandemic. J Clin Res Pediatr Endocrinol 2022;14:267-274.



Address for Correspondence: Rujittika Mungmunpantipantip MD, Private Academic Consultant, Bangkok, Thailand
E-mail: rujittika@gmail.com **ORCID:** orcid.org/0000-0003-0078-7897

Conflict of interest: None declared
Received: 24.03.2022
Accepted: 10.05.2022

©Copyright 2022 by Turkish Society for Pediatric Endocrinology and Diabetes
The Journal of Clinical Research in Pediatric Endocrinology published by Galenos Publishing House.

2. Albuali WH, AlGhamdi NA. Diabetic ketoacidosis precipitated by atypical coronavirus disease in a newly diagnosed diabetic girl. *J Taibah Univ Med Sci* 2021;16:628-631.
3. Eskandarani RM, Sawan S. Diabetic Ketoacidosis on Hospitalization with COVID-19 in a Previously Nondiabetic Patient: A Review of Pathophysiology. *Clin Med Insights Endocrinol Diabetes* 2020;13:1179551420984125.
4. Palermo NE, Sadhu AR, McDonnell ME. Diabetic Ketoacidosis in COVID-19: Unique Concerns and Considerations. *J Clin Endocrinol Metab* 2020;105:dga360.
5. Mungmunpantipantip R, Wiwanitkit V. Diabetic ketoacidosis, COVID-19 and blood viscosity. *J Taibah Univ Med Sci* 2022;17:343-344. Epub 2021 Nov 11
6. Joob B, Wiwanitkit V. Blood viscosity of COVID-19 patient: a preliminary report. *Am J Blood Res* 2021;11:93-95.